Klotho Neurosciences Inc (KLTO): Price Target Chart
The price trend visualization on the GURU.Markets platform demonstrates the dynamics of Klotho Neurosciences Inc (KLTO), which currently stands at 0.00. This biotech firm develops agents to combat brain tissue degradation in US centers and is exploring therapies for Alzheimer's. The project's success relies on the validation of Klotho protein functions and the protection of intellectual property rights for anti-aging technologies. Meanwhile, Klotho Neurosciences Inc (KLTO) operates on a project basis without stable profits, awaiting the completion of clinical trials.
Analytical breakdowns for Klotho Neurosciences Inc (KLTO)
- stock value and consensus price forecast:
- stock exchange capitalization data:
- issuer book value statistics:
- business debt structure and liquidity details:
Debt to Equity Ratio Klotho Neurosciences Inc|KLTO - Long-Term Debt to Capital|Current Liabilities to Capital anewmeds.com|KLTO - Company Total Debt|Debts to Book Capitalization ANEW Medical, Inc.|KLTO - Company Long-Term Debt|Company Short-Term Loans and Borrowings Klotho Neurosciences|Immediate Liquidity anewmeds.com
- earnings and market ratios statistics:
KLTO - Company Net Income|Projected Future Earnings Klotho Neurosciences Inc|KLTO - Price to Earnings Ratio|Future Price to Earnings anewmeds.com|KLTO - Price/Earnings to Growth Ratio|Company Value to EBITDA ANEW Medical, Inc.|KLTO - Operating profit before deduction of amortization|Earnings per share for the last four quarters Klotho Neurosciences|KLTO - Net earnings per share (EPS TTM)|Year-over-year earnings per one share growth for the last 12 months anewmeds.com|KLTO - Earnings per share growth in current year|Expected net earnings per share growth next year Klotho Neurosciences Inc
Summary company analytics:KLTO ANEW Medical
For Klotho Neurosciences Inc (KLTO), whose operations are limited to early-stage drug development and a minimal environmental footprint, the trajectory of analysts' target prices serves as a key indicator of market expectations. This metric aggregates expert forecasts for risk management, allowing investors to balance profit-taking in overheated assets with the prevention of premature exits from a position.
Competitors of Klotho Neurosciences Inc
Analyst Consensus Forecast biogen.com (BIIB)|Price Target Chart Neurocrine Biosciences, Inc. NBIX|Regencell Bioscience Ltd - Price Target Chart|AXSM: Consensus Target|ACADIA Corp - Analyst Forecast Prices|Xenon Pharmaceuticals (XENE) - Price Target Chart|Average Forecast Price vikingtherapeutics.com (VKTX)|Price Target Chart Supernus|Broker Consensus Forecast CPRX (Catalyst Pharma)|Analyst Consensus Forecast DNLI|HRMY - Average Forecast Price|Biohaven Ltd. - Consensus Target|Analyst Consensus Forecast amylyx.com AMLX|TRVI - Price Target Chart|Fair Value Consensus PRAX (Praxis Precision Medicines Inc)|Anavex Corp (AVXL) - Price Target Chart|Average Forecast Price CeriBell EEG (CBLL)|Price Target Chart Prothena Corporation PLC|Analyst Consensus Forecast Alector Therapeutics|Price Target Chart Annexon (ANNX)|Price Target Chart OMER (omeros.com)|Price Target Chart Neurogene Corp NGNE|AC Immune Inc (ACIU) - Average Forecast Price|VYGR: Consensus Target|neumoratx.com - Analyst Forecast Prices|SCLX: Analyst Consensus Forecast|Tevogen Bio Holdings Inc. - Fair Value Consensus|Price Target Chart Alpha Cognition Inc|Average Forecast Price cogrx.com CGTX|Consensus Target IKT (Inhibikase Therapeutics)|SAVA (cassavasciences.com) - Fair Value Consensus|Price Target Chart Assertio ASRT|COYA: Broker Consensus Forecast|VistaGen Therapeutics Inc - Analyst Consensus Forecast|Average Forecast Price Ovid Therapeutics Inc.|ABOS (Acumen Pharmaceuticals) - Consensus Target|cervomed.com (CRVO) - Analyst Consensus Forecast|Price Target Chart Alterity Therapeutics Ltd.|CLNN: Fair Value Consensus|Price Target Chart PepGen Inc. (PEPG)|JUNS - Average Forecast Price|Price Target Chart Relmada Therapeutics RLMD|Analyst Median Target annovisbio.com (ANVS)|Grace Tx - Analyst Consensus Forecast|Firefly Neuroscience, Inc. (AIFF) - Consensus Target|NRSN: Analyst Consensus Forecast|RVPH - Analyst Median Target|MTVA (MetaVia Inc.) - Analyst Consensus Forecast|Average Forecast Price neuraxis.com NRXS|Price Target Chart Helius Medical (HSDT)|passagebio.com - Broker Consensus Forecast|Analyst Consensus Forecast NEUP (Neuphoria Therapeutics)|NERV - Consensus Target|Athira Pharma, Inc. - Analyst Consensus Forecast|Average Forecast Price addextherapeutics.com|alzamend.com (ALZN) - Price Target Chart|CYCN - Analyst Median Target|Consensus Target PTIX|KTTA: Fair Value Consensus|Analyst Consensus Forecast CRGT|Analyst Median Target avenuetx.com|Price Target Chart BrainStorm Cell Therapeutics BCLI|CARA: Broker Consensus Forecast|Chromocell Therapeutics Corporation - Analyst Consensus Forecast|Eliem Therapeutics (ELYM) - Consensus Target|intracellulartherapies.com (ITCI) - Price Target Chart|longboardpharma.com (LBPH) - Analyst Consensus Forecast|Price Target Chart Marinus Pharmaceuticals, Inc.|Price Target Chart NKGN|Consensus Target NRBO (NeuroBo)|Analyst Forecast Prices SAGE|Price Target Chart Synaptogenix, Inc. SNPX|trevena.com (TRVN) - Average Forecast Price|VIGL - Price Target Chart|WENA (Anew Medical Inc.) - Broker Consensus Forecast|CERE: Analyst Consensus Forecast
